Current treatments for metabolic diseases, particularly obesity, often come with unwanted side effects due to a lack of specificity in targeting the central mechanisms that control metabolism. Existing therapies may not effectively reach the specific brain areas responsible for regulating energy balance, leading to broad systemic effects.

Gazella Biotech is developing advanced therapies for metabolic diseases, focusing on obesity, by precisely regulating the central mechanisms that control metabolism. Their technology targets treatments to specific brain areas that regulate metabolism, aiming to improve efficacy and minimize off-target effects. This targeted approach seeks to virtually eliminate the unwanted side effects associated with current obesity treatments. The company leverages innovative technologies to develop drugs that can improve patient outcomes by making new treatments more accessible.

Targeted drug delivery to specific hypothalamic areas that regulate metabolism.

Development of therapies based on small extracellular vesicles (sEVs) to target AMPKα1.

Focus on central mechanisms of metabolic control to address obesity.

Technologies designed for high specificity to minimize off-target effects.

The primary target audience includes individuals suffering from metabolic diseases, particularly obesity, and healthcare providers seeking more effective and targeted treatment options with fewer side effects.